

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

**Notices:**

- Appriss has been selected as the vendor for the PDMP
- The PDMP received two grants: The State Opioid Response (SOR) grant and a partial award of the Bureau of Justice Assistance (BJA) grant.

**Registration**

**Portal**

Number of licensed Veterinarians: 365  
Number of PDMP Veterinarian registrations: 313  
Number of Veterinarians with DEA registrations: 331  
Number of Veterinarians directly dispensing: 63  
Compliance rate (DEA and PDMP registrations): 95%

**AWARxE (PDMP)**

Number registered with the PDMP: 348  
Compliance rate (DEA and AWARE): 95%

**Use**

Review compliance of Federally Schedule II - III from October - December 2020: 1.46%  
205 Dispensations; 3 searched

**MME Use (April 2020 – September 2020)**

Number of patients treated with over 90 MME: 4  
Number of patients treated with over 120 MME: 4  
Number of patients treated with dangerous combinations (benzodiazepines and opioids): 14

**Delinquent Reporters**

Providers who directly dispense are required to report daily. We are currently gathering this information on the renewal applications.

**Recommendations**

- Encourage increased reviewing, including the use of delegates
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations
- Providers should be notified they are not able to prescribe until their registration in AWARxE has been approved
- Encourage licensees to verify their user roles and specialties in AWARxE to improve the accuracy of reporting

Alaska Prescription Drug Monitoring Program  
Summary Prepared for Board of Veterinary Examiners  
January 2021



**MME Use**

June 2020 – October 2020

The CDC recommends that primary care clinicians should reassess evidence of the benefits and risks to the individual when increasing dosage to greater or equal to 50 MME/day and avoid increasing to greater or equal to 90 MME/day when possible due to an increased risk of complications. The CDC also recommends avoiding concurrent benzodiazepine and opioid prescriptions, given the high risk of adverse drug-drug interactions, specifically respiratory depression and death.

CDC checklist for prescribing opioids -

[https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\\_OpiodPrescribeCDC\\_06.2018.pdf](https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDC_06.2018.pdf)

CDC guidelines for prescribing opioids for chronic pain -

[https://www.commerce.alaska.gov/web/portals/5/pub/PDMP\\_OpiodPrescribeCDCPain\\_2018.10.pdf](https://www.commerce.alaska.gov/web/portals/5/pub/PDMP_OpiodPrescribeCDCPain_2018.10.pdf)

Provider Type	# Providers Prescribing at Least Once	# Providers Who Reviewed 0 Patients	# Providers Prescribing >90MME	# Providers Prescribing >120MME	Dangerous Combo	
					Benzo Opioid	Benzo Opioid Carisoprodol
NUR	499	22% (112)	12% (59)	7% (37)	25% (124)	1% (7)
DEN	311	60% (187)	5% (17)	1% (4)	26% (80)	0
MED	1354	31% (421)	20% (273)	12% (165)	32% (438)	2.6% (35)
PA	294	24% (72)	17% (49)	12% (35)	26% (77)	2% (7)
VET	171	76% (130)	2% (4)	2% (4)	6% (10)	0
OPT	2	100% (2)	0	0	0	0